We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Amphastar Pharmaceuticals (AMPH - Free Report) closed the most recent trading day at $55.61, moving +1.85% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.57%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 1.25%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 1.05% over the past month. This has lagged the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.
Investors will be eagerly watching for the performance of Amphastar Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.87, signifying a 19.18% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $174.9 million, indicating a 29.54% increase compared to the same quarter of the previous year.
Investors should also note any recent changes to analyst estimates for Amphastar Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Amphastar Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, Amphastar Pharmaceuticals is holding a Forward P/E ratio of 14.47. This indicates no noticeable deviation in contrast to its industry's Forward P/E of 14.47.
We can additionally observe that AMPH currently boasts a PEG ratio of 0.64. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Generic Drugs industry had an average PEG ratio of 1.33 as trading concluded yesterday.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
Amphastar Pharmaceuticals (AMPH - Free Report) closed the most recent trading day at $55.61, moving +1.85% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.57%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 1.25%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 1.05% over the past month. This has lagged the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% in that time.
Investors will be eagerly watching for the performance of Amphastar Pharmaceuticals in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.87, signifying a 19.18% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $174.9 million, indicating a 29.54% increase compared to the same quarter of the previous year.
Investors should also note any recent changes to analyst estimates for Amphastar Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Amphastar Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, Amphastar Pharmaceuticals is holding a Forward P/E ratio of 14.47. This indicates no noticeable deviation in contrast to its industry's Forward P/E of 14.47.
We can additionally observe that AMPH currently boasts a PEG ratio of 0.64. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Generic Drugs industry had an average PEG ratio of 1.33 as trading concluded yesterday.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.